Quick Answer
Aurinia Pharmaceuticals Inc. reported Net Income Loss of $287.20 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +4,893.1% in Net Income Loss from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$14.10 million | Q2 2019: -$16.38 million | Q3 2019: -$23.45 million | Q4 2019: -$34.46 million | Q1 2020: -$25.93 million | Q2 2020: -$26.54 million | Q3 2020: -$42.13 million | Q4 2020: -$8.07 million | Q1 2021: -$50.38 million | Q2 2021: -$47.01 million | Q3 2021: -$50.26 million | Q4 2021: -$33.32 million | Q1 2022: -$37.63 million | Q2 2022: -$35.52 million | Q3 2022: -$8.99 million | Q4 2022: -$26.05 million | Q1 2023: -$26.21 million | Q2 2023: -$11.49 million | Q3 2023: -$13.45 million | Q4 2023: -$26.88 million | Q1 2024: -$10.75 million | Q2 2024: $722.0 thousand | Q3 2024: $14.35 million | Q4 2024: $1.43 million | Q1 2025: $23.34 million | Q2 2025: $21.51 million | Q3 2025: $31.55 million | Q4 2025: $210.79 million.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Net Income Loss has grown by 641.1%.
- Historical annual values: Fiscal year 2025: $287.20 million | Fiscal year 2024: $5.75 million | Fiscal year 2023: -$78.02 million | Fiscal year 2022: -$108.18 million | Fiscal year 2021: -$180.97 million | Fiscal year 2020: -$102.68 million | Fiscal year 2019: -$88.39 million | Fiscal year 2018: -$53.08 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: